- Home
- CUE vs ORGO Comparison
CUE vs ORGO Comparison
Compare CUE & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | ORGO |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 181.4M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CUE | ORGO |
|---|---|---|
| Price | $27.77 | $1.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $88.00 | $2.00 |
| AVG Volume (30 Days) | 373.8K | ★ 618.5K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.11 | ★ 1600.00 |
| EPS | N/A | ★ N/A |
| Revenue | $27,466,000.00 | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 195.75 | 17.04 |
| 52 Week Low | $0.17 | $1.25 |
| 52 Week High | $45.50 | $7.08 |
Technical Indicators
Market Signals| Indicator | CUE | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 31.82 |
| Support Level | $24.27 | N/A |
| Resistance Level | $33.11 | $2.69 |
| Average True Range (ATR) | 3.36 | 0.06 |
| MACD | -0.54 | 0.01 |
| Stochastic Oscillator | 43.15 | 14.29 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.